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INTRODUCTION 
 
 The influence on the incidence of cardiovascular diseases, as one of the 
most important effect of hormone replacement therapy on mortality of the 
population has been studied extensively for nearly 20 years. But following 
natural, or artificial meanopause due to bilateral ovariectomy, in the lack of 
estrogen treatment the risk of coronary diseases is twice higher than in women 
having received estrogen treatment. In menopausa the function of endothelium 
is weakened gradually: the endothelium-dependent vasodilatation in women 
above the age of 60 can reach the level observed in men. The tight connection 
between the reduced function of endothelium, hypertonia, 
hypercholesterolaemia and atherosclerosis is well-known,  and it might lead to 
increased cardiovascular risk. Therefore the dysfunction of endothelium, as a 
result of the lack of estrogen in menopausa, might play and important role in the 
the elevated mortality due to cardiovascular diseases. Based on these we can 
postulate that hormone replacement therapy might decrease the incidence of 
cardiovascular diseases in menopausa. However, in contrast to the expectations, 
well-known, extensive, randomized chlinical studies, such as Heart and 
Estrogen/Progestin Replacement Study (HERS) and Women’s Health Initiative 
(WHI) have not confirmed the beneficial effect of hormone replacement in 
menopausa. The major problems were the short duration of the studies and the 
involvement of only women already suffering from coronary disease and aged 
between 65 and 70. Long-term estrogen treatment enhances the risk of breast 
and endometrial cancer. Therefore a large scale research work was initiated in 
order to find novel compounds that possess the beneficial characteristics of 
estrogen without being risk factors of cancers. 
The modern idea of selective estrogen receptor modulation (SERM) is 
promising, since we would have a tool for designing drugs that retain their 
estrogen-agonistic effect in the target tissues, such as bones, circulatory or 
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central nervous system without stimulating other tissues, like breasts, where 
estrogens can act as oncogens. One of these SERM compounds is raloxifene, 
which was studied by us as well. 
Carbon monoxide (CO) produced by heme-oxygenase (HO) enzyme system 
takes part in estrogen-mediated cardiovascular protection. A range of 
pharmacons can play role in certain inflammatory (5-amino-salicylic acid) and 
anti-proliferative (paclitaxel) protective mechanisms through the induction of 
HO system. Several beneficial features of paclitaxel makes it a promising 
candidate for local drug therapy of extensive arterial smooth muscle cell 
proliferation in restenosos following balloon angioplasty or stent implantation. 
 
PURPOSES 
 
The clinical use of new generation SERM compounds might be a potential 
alternative of hormone replacement therapy in certain stages of menopausa. The 
requirement for the long-term application of SERM compounds is that they have 
to be safe in diseases appear more and more frequently following menopausa, 
such as ischaemic heart disease and certain alterations of the central nervous 
system.   
We studied the effects of the lack of sex steroids, as well as estrogen and 
raloxifene treatment. 
 
1. Examination of the cardiovascular effect of the lack of estrogen 
1.1. How does the lack of E2 influence plasma AVP-level, basal blood pressure 
and tendency to heart ischaemia? How is blood pressure as response to AVP, 
vessel contraction and heart perfusion altered in the lack of estrogen? 
1.2. How does estradiol monotherapy and raloxifene substitution influence 
plasma AVP-level, basal blood pressure and tendency to heart ischaemia, as 
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well as blood pressure as response to AVP, aorta contraction and heart perfusion 
as compared to the state of the lack of estrogen? 
1.3. We studied the estrogen-mediated cardiovascular role of HO enzyme. 
2. Local drug therapy of cardiovascular diseases 
2.1. By determining the tissue paclitaxel concentration of the dilated artery wall 
and adjacent segments we intended to confirm the uptake of paclitaxel into the 
wall of coronary artery following the treatment of single segments of the 
coronary artery, as well as bifurcations by drug eluting balloon. 
 
Further plans: To prove that paclitaxel develops its anti-proliferative effect 
through the induction of HO enzyme system, and to study the role of the 
estrogen-mediated mechanism in domestic pig model. 
 
METHODS 
 
Experimental processes, treatments 
In our first series of experiments we studied 230-250g-weighted, 10-12-week-
old male and female Wistar rats. Females were examined in the morning of 
estrus and in diestrus phase. A certain group was subjected to bilateral 
ovariectomy. Distinct groups of the ovariectomized females underwent a 2-
week-long estrofem- (E2: 0.10 mg/kg/day, per os, once daily) or raloxifene- 
(R0.11: 0.11 mg/kg/day; R0.33: 0.33 mg/kg/day; R1: 1.0 mg/kg/day, per os, 
once daily) treatment. The acticity of enzymes was blocked by tin-
protoporphyrin IX (SnPP: 30.0 µg/kg, s.c., pH 7.40, 24- and 1-hour-long 
pretreatment).  
In the second phase of our experiments we determined the paclitaxel 
concentration in the coronary arteries - left descending (LAD), left circumflex 
(LCx) and right (RCA) - of 18-30-kg-weighted domestic pigs 1.5, 12, 24 and 48 
following Dior-balloon inflation (2×30 s, 6 atm). Furthermore, bifurcation 
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intervention was performed on 6 arteries as described: first the main, then the 
side branches were dilated by a Dior-balloon (6 atm, 2x30s), which was 
followed kissing balloon dilatation. 
During the experiments the care and laboratory use of the animals were 
performed in accordance with the concerning regulations of the EU and with the 
approval of the Ethical Committee of the Institute. 
 
Determination of plasma AVP-level 
Plasma AVP-level was determined by radioimmunoassay (RIA) technique, and 
expressed in pg/ml. 
 
Measurement of surviving aorta ring contraction in rat 
The tension of aorta was measured in vitro with the aid of the software ISOSYS. 
We examined the contraction as response to 2.0 µg/ml AVP and expressed 
results as the pressure of aorta ring (g/mg aorta ring). 
 
Determination of HO enzyme activity 
We measured the amount of bilirubin formed during the conversion of heme 
using spectrophotometric method, and expressed results as nM bilirubin/h/mg 
protein. 
 
Examination of HO-1 enzyme expression 
The expression of HO-1 enzyme was determined by using Western blot. The 
results were expressed as percentage following densitometrical analysis. 
 
Measurement of basal blood pressure and the response to AVP 
The animals were subjected to phentolamine treatment (10.0 mg/kg, i.p.) 
following anesthesy performed with 30 % urethane (0.50 ml/100 g, i.p.), and 
after the stabilization of blood pressure AVP (0.02; 0.06; 0.18 µg/kg, i.v.) was 
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injected into the lateral tail vein. The increase in blood pressure was determined 
(maximal increase in % as compared to the basal value) in the right carotid 
artery. Results were evaluated by the software HAEMOSYS program 
(Experimetria, UK, London). 
 
Determination of heart perfusion according to Langendorff 
10-20 minutes prior to cervical dislocation the animals received heparin 
injection (500 IU, i.p.), then their hearts were placed to a Langendorff perfusion 
column. Heart perfusion as response to AVP (1.0; 3.0; 10.0 µg) was measured 
following a stabilization period of 15 minutes, and results were expresed as % as 
compared to the basal value. 
 
Experimental angina model evoked by adrenalin and phentolamine 
Mean arterial blood pressure and surface II. ECG was measured and analyzed 
with the aid of HEMOSYS computerized system. The changes in ST depression 
was used for determining heart ischaemia. In epinephrine-phentolamine model a 
single dose of epinephrine (10.0 µg/kg), and 30 s later α-adrenoceptor antagonist 
phentolamine (15.0 mg/kg) was administered into the tail vein of the animals. 
Changes in ECG and blood pressure were monitored simultaneously. 
 
Determination of paclitaxel concentration 
The concentration of paclitaxel was determined in plasma, LAD, LCx, and RCA 
by using high-performance liquid chromatography (HPLC), and tissue 
concentrations were expressed as µM/L. 
 
Statistical analysis 
Data are expressed as mean ± S.E.M. The results of Western-blot experiments 
are demonstrated in representative photos. Statictical significance was 
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determined by Mann W. test, and differences were considered as significant if 
p< 0.05.  
In experiments with pigs the continuous parameters of the groups were 
expressed as mean ± S.D. Tissue paclitaxel concentrations measured in the 
distinct arterial segments (proximal, middle and distal) were grouped, and 
grouped mean values were compared by unpaired t-test. Differences were 
considered as significant if p< 0.05. Statistical analysis was performed with the 
aid of the software SPSS for Windows version 11.5. 
 
DISCUSSION 
 
The lack of endogenous estrogen following experimental menopausa resulted in 
elevated plasma AVP level, increased basal blood pressure and ST depression, 
which alterations could be normalized by hormone replacement or raloxifene 
therapy. Treatment with estradiol or raloxifene restored the ability of responding 
to AVP both in heart and aorta, through significantly reducing the enhanced 
aorta contraction observed in the lack of the sex steroid, and increased heart 
perfusion. This alteration means that in the lack of endogenous estrogen the risk 
of hypertonia is enhanced, and that following hormone replacement blood 
pressure is normalized. Results gained from measuring surviving aorta 
contraction in rat show that the reason for the vascular response to AVP is the 
direct effect of estrogen and raloxifene on the smooth muscle of the vessels. 
According to our results in ovariectomized rats plasma AVP level and arterial 
blood pressure are elevated, the increase in surviving aorta ring contraction and 
the decrease in Langendorff heart perfusion are much more expressed than in 
intact females. Estrogen replacement or raloxifene treatment abolish the 
increased blood pressure and the extended pressor response to AVP. By 
intensifying the expression and activity of NOS and HO enzimes, as well as 
enhancing the release of other vasodilatators, while reducing the synthesis and 
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secretion of vasoconstrictors, estrogen and raloxifene favor vasodilatation. 
Supporting these findings we have observed that the lack of endogenous 
estrogen results in the inhibition of NOS and HO enzimes located in the vessels, 
which, according to our conclusions, explains the enhanced sensitivity of the 
vessel system to AVP. The expression and activity of HO enzymes are also 
significantly lower in the cardiac left ventricle of ovariectomized rats than those 
in control females possessing intact estrogen formation. While the lack of 
estrogen resulted in decreased level of HO, the 2-week-long estrogen or 
raloxifene treatment restored the activity and expression of HO enzymes to the 
level observed in control females. According to our results concerning cardiac 
muscle the expression of HO shows sexual dimorphism and and cycle-
dependence. We observed a lower level of of activity and expression also in 
males as compared to females in estrus phase. However, having examined the 
distinct estrogen fullness states we did not detect significant differences in 
activity between estrus and diestrus phase. Concerning HO-activity in the aorta 
the results were entirely contrary, which might be explained in differences 
between the distinct tissues. 
Both enzymes up-regulated in an estrogen-mediated manner - NOS and  HO – 
play role in the reduction of the tendency of cardiac muscle to ischaemia. 
Following treatment with L-NAME – a non-selective NOS inhibitor – or SnPP – 
inhibitor of HO – cardiac ischaemia, blood pressure and heart perfusion became 
significantly expressed, which support the estrogen-mediated regulator role of 
NOS and HO in cardiovascular protection. Based on our results we assume that 
estrogen and raloxifene substitution lead to an increased level of NO, as well as 
the reaction products of HO, and these mediators enhance the beneficial effect 
of each other. Therefore these two mechanisms are considered to be the most 
important participants in the protection of heart from ischaemia. 
In our further experiments we have proved that paclitaxel – a compound used in 
clinical practice due to its ability to induce HO e
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as an anti-proloferative agent – can be uptaken within a short time into coronary 
vessels in a concentration that is sufficient for its anti-proloferative effect. 
According to the literature paclitaxel induces the expression of HO-1 gene 
efficiently. In the present study, measuring tissue paclitaxel concentration in 
single or bifurcation segments of porcine coronary artery 1.5, 12, 24 and 48 
post-dilatation we confirmed the efficacy of the delivery of the compound by a 
Dior-balloon. Paclitaxel is supposed to deliver its anti-proloferative effect 
through the HO system, therefore one of our further plans is to confirm its 
relationship with this system, and to examine the estrogen-mediated effect in 
domestic pig model. 
 
SUMMARY 
 
According to our observation SERM raloxifene provides cardiovascular 
protection in the lack of estrogen through acting as an estrogen agonist in the 
regulation of HO enzyme system. The effect of estradiol on miogenic tone 
appears to be an endothelium-dependent response mediated by NO synthesis, 
and our results demonstrate that estrogen and raloxifene takes part in the 
protective mechanisms of the cardiovascular system through the up-regulation 
of HO enzymes. Furthermore, we can state that endogenous AVP is likely to 
play role in the enhanced vessel contractility in menopausa. 
Short-term local delivery of paclitaxel into the coronary artery by a drug-coated 
balloon is sufficient for providing the appropriate tissue concentration of the 
compound, which can effectively inhibit the neointimal growth of coronary 
arteries. 
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